CardioVascular BioTherapeutics, Inc. - Financial and Strategic Analysis Review
http://www.companiesandmarkets.com/Summary-Company-Profile/cardiovascular-biotherapeutics,-inc.-financial-and-strategic-analysis-review-85358.asp
- Market - Healthcare and Medical
- Published Date - 13/06/2009
- Report Type - Company Profile
- Country - Global
- Number of Pages - 19
- Electronic - £73.00
- Site Licence - £145.00
- Corporate Licence - £217.00
Report Summary
CardioVascular BioTherapeutics, Inc. - Financial and Strategic Analysis Review
Summary
Cardiovascular Biotherapeutics, Inc. (CVBT) is a biopharmaceutical company. It is engaged in the development of protein drugs for the treatment of regenerative cardiovascular diseases. The company's development stage product facilitates the growth of new blood vessels in the heart, tissues and organs. Its primary product candidate FGF-1 (141), is designed to facilitate the growth of new blood vessels in the heart and other tissues and organs with an impaired vascular system and is currently undergoing Phase II clinical trials for treatment of coronary heart disease. The company is headquartered in Las Vegas, United States.
The CardioVascular BioTherapeutics, Inc. - Financial and Strategic Analysis Review is an in-depth business, strategic and financial analysis of CardioVascular BioTherapeutics, Inc.. The report provides a comprehensive insight into the company, including business structure and operations, executive biographies and key competitors. The hallmark of the report is the detailed strategic analysis of the company. This highlights its strengths and weaknesses and the opportunities and threats it faces going forward.
Scope
- Provides key company information for business intelligence needs.
- The company’s strengths and weaknesses and areas of development or decline are analyzed. Financial, strategic and operational factors are considered.
- The opportunities open to the company are considered and its growth potential assessed. Competitive or technological threats are highlighted.
- The report contains critical company information – business structure and operations, the company history, major products and services, key competitors, key employees and executive biographies, different locations and important subsidiaries.
- The report provides detailed financial ratios for the past five years as well as interim ratios for the last four quarters.
- Financial ratios include profitability, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Reasons to buy
- A quick "one-stop-shop" to understand the company.
- Enhance business/sales activities by understanding customers’ businesses better.
- Get detailed information and financial and strategic analysis on companies operating in your industry.
- Identify prospective partners and suppliers – with key data on their businesses and locations.
- Capitalize on competitor's weaknesses and target the market opportunities available to them.
- Compare your company’s financial trends with those of your peers / competitors.
- Scout for potential acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Table of Contents
Table Of Contents
Key Information 1
Key Ratios 1
Share Data 1
Performance Chart 1
Key Facts 4
Business Description 4
Major Products and Services 5
Overview 5
History 6
SWOT Analysis Overview 7
Overview 7
CardioVascular BioTherapeutics, Inc. - Strengths 7
Proprietary Technology 7
Agreements 7
CardioVascular BioTherapeutics, Inc. - Weaknesses 7
Increased Presence of Debt 7
Dependence on Single Supplier 7
CardioVascular BioTherapeutics, Inc. - Opportunities 8
Market Potential 8
Molecules in Clinical Development 8
Marketing Strategy 8
CardioVascular BioTherapeutics, Inc. - Threats 8
Competition 8
Tightening of FDA’s Regulatory Oversight 8
Emergence of Biogenerics/Biosimilars 9
Key Competitors 10
Key Employees 10
Key Employee Biographies 11
Company Statement 12
Locations And Subsidiaries 14
Head Office 14
Other Locations & Subsidiaries 14
Financial Ratios 15
Capital Market Ratios 15
Annual Ratios 15
Interim Ratios 15
Ratio Charts 16
Appendix 17
Methodology 17
Ratio Definitions 17
About Global Markets Direct 20
Contact Us 20
Disclaimer 20
List of Tables
CardioVascular BioTherapeutics, Inc., Key Facts 1
CardioVascular BioTherapeutics, Inc., Key Ratios 1
CardioVascular BioTherapeutics, Inc., Share Data 1
CardioVascular BioTherapeutics, Inc., Key Facts 4
CardioVascular BioTherapeutics, Inc., History 6
CardioVascular BioTherapeutics, Inc., Key Employees 10
CardioVascular BioTherapeutics, Inc., Key Employee Biographies 11
CardioVascular BioTherapeutics, Inc., Other Locations 14
CardioVascular BioTherapeutics, Inc., Ratios based on current share price 15
CardioVascular BioTherapeutics, Inc., Annual Ratios 15
CardioVascular BioTherapeutics, Inc., Interim Ratios 15
Currency Codes 17
Capital Market Ratios 17
Equity Ratios 18
Profitability Ratios 18
Cost Ratios 18
Liquidity Ratios 19
Leverage Ratios 19
Efficiency Ratios 19
List of Figures
CardioVascular BioTherapeutics, Inc., Performance Chart (2003 - 2007) 1
CardioVascular BioTherapeutics, Inc., Ratio Charts 16